PD-L1 expression is positively correlated with a deficiency in DNA MMR genes and microsatellite instability in cancer cells and is implicated in metastatic CRPC [25,26], making it possible to use PD-1/PD-L1 inhibitors in order to expose tumor cells to host immune attack. Here, PDCD1 is linked to cancer.